Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma

Published:2014-02 Issue:2 Volume:83 Page:259-264
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Sun Jong-Mu,Lira Maruja,Pandya Kinnari,Choi Yoon-La,Ahn Jin Seok,Mao Mao,Han Joungho,Park Keunchil,Ahn Myung-Ju,Kim Jhingook

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference27 articles.

1. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

2. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study;Camidge;Lancet Oncol,2012

3. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study;Seto;Lancet Oncol,2013

4. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2013

5. Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC;Shaw;J Clin Oncol,2013

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer;Cancers;2023-09-14

2. Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?;Current Oncology;2023-05-16

3. ALK-positive advanced non-small cell lung cancer patients with poor performance status: Outcomes in a real-world scenario;ecancermedicalscience;2022-06-07

4. Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: A Meta-Analysis;Frontiers in Oncology;2021-06-02

5. An insight into lung cancer: a comprehensive review exploring ALK TKI and mechanisms of resistance;Bosnian Journal of Basic Medical Sciences;2021-05-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3